PT-141 vs Melanotan-2
PT-141 (Bremelanotide) and Melanotan II both act on melanocortin receptors, but PT-141 was specifically developed from Melanotan II to isolate the sexual function effects. PT-141 is the only one of the two that has achieved FDA approval -- specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Side-by-Side Comparison
| Category | PT-141 | Melanotan-2 |
|---|---|---|
| Mechanism of action | Selective melanocortin-4 receptor (MC4R) agonist. Acts on the central nervous system to increase sexual arousal and desire. Does not affect melanin production or tanning. | Non-selective melanocortin receptor agonist (MC1R through MC5R). Stimulates melanin production (tanning), increases sexual arousal (MC4R), and suppresses appetite (MC4R). |
| Primary research area | Female hypoactive sexual desire disorder (HSDD), male erectile dysfunction. FDA-approved for female HSDD (Vyleesi, 2019). | Originally developed for skin cancer prevention (tanning without UV). Sexual function effects were discovered as a side effect. Not FDA-approved. |
| Evidence level | FDA-approved (Vyleesi, 2019) for HSDD in premenopausal women. Phase III trials completed. Published human efficacy and safety data. | Phase I/II trials for tanning (Clinuvel). Not pursued for FDA approval in the US. Associated with risks including nausea and potential mole changes. |
| Administration route | Subcutaneous injection (auto-injector). FDA-approved route. Used as needed, ~45 minutes before anticipated activity. | Subcutaneous injection. Typically used on a loading/maintenance schedule for tanning effects. |
| Typical research dosing | 1.75 mg subcutaneous as needed (FDA-approved dose). No more than once per 24 hours, no more than 8 doses per month. | Tanning: loading phase of 0.25-0.5 mg daily for 1-2 weeks, then maintenance 1-2x/week. Doses vary widely in community use. |
| Key studies/evidence | RECONNECT phase III trials leading to FDA approval. Demonstrated statistically significant improvement in sexual desire in premenopausal women with HSDD. Known side effects: nausea, flushing, headache. | Dorr et al. (1996) — early human studies on tanning. Hadley (2005) — review of melanocortin system and sexual function. Multiple case reports on adverse effects including mole darkening. |
Can They Be Stacked?
Not recommended to combine. Both act on melanocortin receptors, and combining them would increase risk of side effects (nausea, blood pressure changes) without clear additive benefit for sexual function. PT-141 alone provides the targeted effect with a known safety profile.
Verdict
PT-141 is the clear choice for sexual function -- it's FDA-approved, has a well-defined safety profile, and targets the relevant receptor (MC4R) selectively. Melanotan II's broader receptor activity produces tanning but also more side effects and safety concerns. The FDA specifically chose to develop PT-141 from Melanotan II to isolate the sexual function benefit while reducing off-target effects.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.